EXCO Resources, Inc. Schedules Second Quarter 2016 Results and Conference Call
Get Alerts XCO Hot Sheet
Join SI Premium – FREE
DALLAS--(BUSINESS WIRE)-- EXCO Resources, Inc. (NYSE: XCO) today announced that it will be releasing second quarter 2016 results on Tuesday, August 2, 2016, after the market closes.
EXCO will host a conference call on Wednesday, August 3, 2016, at 9:00 a.m. (central time) to discuss the results and respond to questions. Please call (800) 309-5788 if you wish to participate, and ask for the EXCO conference call ID# 26008691. The conference call will also be webcast on EXCO’s website at www.excoresources.com under the Investor Relations tab. Presentation materials related to this release will be posted on EXCO’s website prior to the conference call.
A digital recording will be available starting two hours after the completion of the conference call until August 31, 2016. Please call (800) 585-8367 and enter conference call ID# 26008691 to hear the recording. A digital recording of the conference call will also be available on EXCO’s website.
About EXCO
EXCO Resources, Inc. is an oil and natural gas exploration, exploitation, acquisition, development and production company headquartered in Dallas, Texas with principal operations in Texas, North Louisiana and Appalachia.
Additional information about EXCO Resources, Inc. may be obtained by contacting Chris Peracchi, EXCO’s Vice President of Finance and Investor Relations, and Treasurer, at EXCO’s headquarters, 12377 Merit Drive, Suite 1700, Dallas, TX 75251, telephone number (214) 368-2084, or by visiting EXCO’s website at www.excoresources.com. EXCO’s SEC filings and press releases can be found under the Investor Relations tab.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160711005179/en/
EXCO Resources, Inc.
Chris Peracchi, 214-368-2084
Source: EXCO Resources, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FORT Robotics to go public via SPAC deal valued at $557 million
- FDA grants fast track status to BlossomHill's lung cancer drug BH-30643
- Helus Pharma names chief people officer, adds CNS expert to advisory board
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share